#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14402	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2319	754.8	0	.	n	.	0	A69G	SNP	69	69	A	445	445	G	887	G,A	886,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14402	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2319	754.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1826	1826	T	966	T,G,C	964,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14402	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2319	754.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1560	1560	C	890	C,T	888,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14402	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2319	754.8	0	HET	.	.	.	T287C,G	.	287	287	T	663	663	T	843	T,C,G	624,218,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24226	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4157	727.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1974	1974	A	1035	A,T,G	1033,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24226	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4157	727.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2608	2608	C	814	C,A	813,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24226	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4157	727.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2682	2682	A	775	A	774	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24226	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4157	727.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3234	3234	C	841	C,T	839,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2158	folP	852	852	99.88	folP.l15.c17.ctg.1	2041	131.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1005	1007	AAA	221;222;222	A;A;A,G,C	221;222;220,1,1	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2158	folP	852	852	99.88	folP.l15.c17.ctg.1	2041	131.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1236	1238	AGC	220;221;220	A;G;C	220;221;220	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5048	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3861	163.1	1	SNP	p	S91F	0	.	.	271	273	TCC	825	827	TCC	196;197;196	T;C;C	196;197;196	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5048	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3861	163.1	1	SNP	p	D95N	0	.	.	283	285	GAC	837	839	GAC	202;202;201	G;A;C	202;202;201	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5048	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3861	163.1	1	SNP	p	D95G	0	.	.	283	285	GAC	837	839	GAC	202;202;201	G;A;C	202;202;201	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1956	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1747	139.1	1	SNP	p	G45D	0	.	.	133	135	GGC	710	712	GGC	225;225;224	G;G,T;C	225;224,1;224	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1144	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1475	96.9	0	.	n	.	0	A197.	DEL	197	197	A	774	774	A	235	A,T	233,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4900	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3473	176.0	1	SNP	p	D86N	0	.	.	256	258	GAC	864	866	GAC	214;212;211	G;A,C;C	214;210,2;211	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4900	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3473	176.0	1	SNP	p	S87I	0	.	.	259	261	AGT	867	869	AGT	211;209;209	A,G,T;G,T;T	207,3,1;208,1;209	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4900	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3473	176.0	1	SNP	p	S87W	0	.	.	259	261	AGT	867	869	AGT	211;209;209	A,G,T;G,T;T	207,3,1;208,1;209	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4900	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3473	176.0	1	SNP	p	S87R	0	.	.	259	261	AGT	867	869	AGT	211;209;209	A,G,T;G,T;T	207,3,1;208,1;209	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4900	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3473	176.0	1	SNP	p	S88P	0	.	.	262	264	TCC	870	872	TCC	210;208;212	T,G;C,A;C,A	208,2;207,1;211,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4390	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3164	173.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1791	1793	GGC	214;213;214	G,T;G;C	213,1;213;214	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	0	.	p	.	0	K8E	NONSYN	22	24	AAG	617	619	GAG	159;161;158	G;A;G,A	159;161;156,2	.	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1526	1528	GCA	220;221;220	G,T;C;A	219,1;221;220	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1529	1531	ATC	221;221;222	A,C;T,C;CAAA,CAA	220,1;220,1;212,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1541	1543	GTG	214;215;218	G;T,C;G	214;214,1;218	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1541	1543	GTG	214;215;218	G;T,C;G	214;214,1;218	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2045	2047	ACC	240;239;241	A;C;C,A,T	240;239;239,1,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2099	2101	GCG	235;234;234	G;C,G;G	235;233,1;234	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2099	2101	GCG	235;234;234	G;C,G;G	235;233,1;234	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2222	2224	GGC	204;206;207	G;G;C,T	204;206;206,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2231	2233	GGC	209;212;214	G,T;G;C,A	208,1;212;213,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	3848	penA	1749	1749	99.94	penA.l6.c4.ctg.1	2925	164.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2249	2251	CTG	218;217;216	C,G,A;T,G;G,T	216,1,1;216,1;215,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5536	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3692	186.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1959	1961	CCG	234;237;235	C;C;G,A	234;237;234,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2374	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2263	130.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	827	827	C	187	C,G	186,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	32	34	TTA	24;26;29	T;T;A	24;26;29	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	77	79	CAT	58;58;58	C;A;T	58;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	80	82	AGT	58;58;58	A;G;T	58;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	89	91	TAC	58;58;58	T;A;C	58;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	179	181	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	191	193	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	194	196	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	200	202	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	206	208	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	212	214	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	215	217	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	218	220	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	244	90.57	porB1a.l15.c4.ctg.2	358	26.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	224	226	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	100	94.0	porB1a.l15.c4.ctg.3	183	55.3	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	63;60;56	A;C;G	63;60;56	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	298	porB1a	984	100	94.0	porB1a.l15.c4.ctg.3	183	55.3	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	19;17;15	C;A;A	19;17;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	628	630	GAA	236;239;236	G;A,C;A	236;237,2;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	916	918	GAT	251;250;250	G;A;T	251;250;250	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1039	1041	TCA	239;242;244	T;C;A	239;242;244	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1168	1170	GTC	213;214;213	G;T,G;C	213;213,1;213	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1180	1182	TCT	203;202;202	T,A;C,A;T	202,1;201,1;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1498	1500	GCA	200;202;201	G,T;C,A;A	199,1;201,1;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	1	SNP	p	G120K	1	.	.	358	360	AAG	874	876	AAG	252;253;254	A,C;A;G,C	251,1;253;253,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	1	SNP	p	D121N	0	.	.	361	363	GAC	877	879	GAC	255;256;255	G;A;C,A	255;256;254,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2706	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	2005	168.0	1	SNP	p	A121D	1	.	.	361	363	GAC	877	879	GAC	255;256;255	G;A;C,A	255;256;254,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9626	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5220	229.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2168	2170	AAT	272;268;268	A;A;T	272;268;268	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1426	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1503	118.0	1	SNP	p	V57M	1	.	.	169	171	ATG	848	850	ATG	255;257;255	A;T;G	255;257;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
